Connection

Charles Bennett to Biosimilar Pharmaceuticals

This is a "connection" page, showing publications Charles Bennett has written about Biosimilar Pharmaceuticals.
Connection Strength

7.874
  1. Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
    View in: PubMed
    Score: 0.800
  2. Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions. Cancer Treat Res. 2022; 184:41-51.
    View in: PubMed
    Score: 0.742
  3. The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
    View in: PubMed
    Score: 0.702
  4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
    View in: PubMed
    Score: 0.688
  5. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.610
  6. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
    View in: PubMed
    Score: 0.609
  7. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
    View in: PubMed
    Score: 0.596
  8. Friction in the Path to Use of Biosimilar Drugs. N Engl J Med. 2018 05 31; 378(22):2148.
    View in: PubMed
    Score: 0.579
  9. Biosimilars-Curb Your Enthusiasm. JAMA Oncol. 2017 11 01; 3(11):1467-1468.
    View in: PubMed
    Score: 0.556
  10. Challenges to Biosimilar Substitution. JAMA. 2017 09 26; 318(12):1186.
    View in: PubMed
    Score: 0.552
  11. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
    View in: PubMed
    Score: 0.525
  12. Japanese regulatory authority's perspective on biosimilars - authors' reply. Lancet Oncol. 2015 Mar; 16(3):e102.
    View in: PubMed
    Score: 0.462
  13. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
    View in: PubMed
    Score: 0.453
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.